References
- Barlogie B, Shaughnessy J, Epstein J, Sanderson R, Anaissie E, Walker R, Tricot G. Plasma cell myeloma. Williams Hematology, 7th ed, L A Lichtman, E Beutler, T J Kipps, U Seligsohn, K Kaushansky, J T Prchal. McGraw-Hill, New York 2006; 1501–1533
- Jacobsen D R, Seldin D C, Buxbaum J N. The amyloidoses. Williams Hematology, 7th ed, L A Lichtman, E Beutler, T J Kipps, U Seligsohn, K Kaushansky, J T Prchal. McGraw-Hill, New York 2006; 1535–1548
- Ma C X, Lacy M Q, Rompala J F, Dispenzieri A, Rajkumar S V, Greipp P R, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104: 40–42
- Greipp P R, San Miguel J, Durie B G, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420
- Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
- Hussein M A, Wood L, Hsi E, Karam M, Elson P, Bukowski R M. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95: 2160–2168
- Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
- Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
- Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S R, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
- Dispenzieri A, Lacy M Q, Zeldenrust S R, Hayman S R, Kumar S K, Geyer S M, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–470
- Sanchorawala V, Wright D G, Rosenzweig M, Finn K T, Fennessey S, Zeldis J B, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–496
- Revlimid® (lenalidomide) package insert. Celgene Corporation, Summit NJ 07901
- List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
- Montagut C, Bosch F, Villela L, Rosinol L, Blade J. Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma 2004; 45: 1711–1712
- Selden D C, Choufani E B, Dember L M, Wiesman J, Berk J L, Falk R H, et al. Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis. Clin Lymphoma 2003; 3: 241–246
- Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949–2951
- Chen N, Lau H, Kong L, Kumar G, Zeldis J B, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47: 1466–1475